We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Company Offers Reliable Microarray Processing and Data

By Biotechdaily staff writers
Posted on 03 May 2007
A pharmacogenomics and molecular biology company offers microarray processing and data that is reliable, reproducible, and of high quality.

Agilent Technologies, Inc., (Palo Alto, CA, USA) and Cogenics (Morrisville, NC, USA), a division of Clinical Data, Inc., have announced that Cogenics is the first certified microarray service provider for Agilent's microRNA (miRNA) microarrays. More...
With this certification, Cogenics becomes the initial service provider to offer expression profiling of miRNA on the Agilent platform, giving scientists in research institutions and drug discovery programs immediate access to this tool for understanding gene regulation.

Cogenics received the certification after its laboratory completed training and passed a rigorous set of assessments that included proficiency in analyzing Agilent 60 mer oligo microarrays using the complete Agilent system: sample quality control using the Agilent 2100 Bioanalyzer; sample labeling using Agilent reagents and protocols; hybridization using SureHyb chambers; microarray analysis using the Agilent scanner and feature extraction software; and final data analysis using the GeneSpring bioinformatics platform.

"We're pleased to be the first Agilent Certified Service Provider for this platform as miRNA is generating a great deal of interest within the academic and drug discovery research communities. There were significant scientific and quality hurdles to overcome and area expertise required for Cogenics to receive this certification from Agilent. Our achievement continues to demonstrate Cogenics' leadership capabilities in this and related areas. The addition of this service to the comprehensive Cogenics product and services portfolio furthers our commitment to provide scientists with the most cutting edge and advanced range of services in the industry,” said Robert Bondaryk, Ph.D., senior vice president and general manager of Cogenics.

"We've enjoyed a long, productive relationship with Cogenics as an Agilent-Certified Microarray Service Provider for gene expression and CGH, and we congratulate Cogenics on expanding their portfolio of emerging applications offered to researchers,” said Yvonne Linney, Agilent vice president and general manager, Genomics.


Related Links:
Agilent
Cogenics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.